A randomized, controlled, crossover pilot study of losartan for pediatric nonalcoholic fatty liver disease

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in children, and currently, there are no FDA-approved therapies. Plasminogen activator inhibitor-1 (PAI-1) is elevated in children with NAFLD and associated with increased disease severity. Losartan potassium (losa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pilot Feasibility Stud
Autors principals: Vos, Miriam B., Jin, Ran, Konomi, Juna V., Cleeton, Rebecca, Cruz, Jessica, Karpen, Saul, Rodriguez, Dellys Soler, Frediani, Jennifer K., McCracken, Courtney, Welsh, Jean
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5987658/
https://ncbi.nlm.nih.gov/pubmed/29992039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40814-018-0306-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars